Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
January 6th, 2023
2.3K views
Here, intra-peritoneal injection of leukemia cells is utilized to establish and propagate acute myeloid leukemia (AML) in mice. This new method is effective in the serial transplantation of AML cells and can serve as an alternative for those who may experience difficulties and inconsistencies with intravenous injection in mice.
Overview
This protocol describes a method for establishing and propagating acute myeloid leukemia (AML) in mice through intra-peritoneal injection of leukemia cells. This technique offers a more convenient and cost-effective alternative to traditional intravenous injection methods.
Key Study Components
Area of Science
- Oncology
- Hematology
- Animal Models
Background
- Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow.
- Traditional methods of AML cell transplantation can be challenging and inconsistent.
- Intra-peritoneal (IP) injection may provide a more reliable method for developing AML models in mice.
- This study compares the effectiveness of IP injection with conventional methods.
Purpose of Study
- To establish a reliable mouse model of AML using IP injection of leukemia cells.
- To evaluate the efficiency of this method compared to intravenous injection.
- To assess the differences in AML generation from various cell types.
Methods Used
- Isolation of lin-negative cells and SK cells from donor mice.
- Intra-peritoneal injection of leukemic cells into 8 to 10-week-old CD45.1 female C57BL/6J mice.
- Surgical preparation of mice for injection, including sterilization and incision.
- Monitoring the development of AML in the injected mice.
Main Results
- IP injection successfully developed a mouse model of AML.
- No significant difference was observed in AML generation between lin-negative cells and SK cells.
- The IP method proved to be more convenient and less expensive than traditional methods.
- Results indicate the potential for broader application of this technique in AML research.
Conclusions
- Intra-peritoneal injection is an effective method for establishing AML in mice.
- This technique can enhance the reliability of AML research models.
- Further studies may explore the implications of using different cell types for AML induction.
Frequently Asked Questions
What is acute myeloid leukemia (AML)?
AML is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells.
Why is intra-peritoneal injection used?
IP injection is used because it is more convenient and less expensive than traditional intravenous methods, while still effectively establishing AML in mice.
What are lin-negative cells?
Lin-negative cells are a subset of hematopoietic stem cells that lack lineage-specific markers, making them suitable for studying leukemia.
How does this method compare to intravenous injection?
The IP injection method is found to be more convenient and less expensive, with no significant differences in the effectiveness of AML generation.
What are the implications of this study?
This study suggests that IP injection can be a reliable alternative for researchers studying AML, potentially improving experimental consistency.
Executive Industry Relevance
Robust murine models of acute myeloid leukemia (AML) are essential for preclinical evaluation of novel therapeutics targeting leukemia stem cells and relapse mechanisms. The intra-peritoneal transplantation protocol offers a reproducible, scalable, and less technically demanding alternative to retro-orbital injection, supporting consistent disease induction and serial transplantation. This approach enhances predictive confidence in early-stage target validation and accelerates translational research continuity across the AML discovery pipeline.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rigorous interrogation of AML therapeutic hypotheses in a controlled in vivo system.
- Facilitates biological de-risking by supporting functional validation of leukemia stem cell targets.
- Supports predictive confidence for portfolio triage by enabling serial transplantation and disease propagation studies.
Screening & Assay Development
- Provides a validated, reproducible murine AML model for downstream compound screening workflows.
- Standardizes disease induction, improving assay reproducibility and quantitative output consistency.
- Enables scalable model generation for parallel evaluation of multiple therapeutic candidates.
Translational & Preclinical Research
- Aligns with disease-relevant biology by recapitulating AML infiltration in blood, bone marrow, spleen, and liver.
- Supports continuity from discovery through preclinical validation by enabling serial transplantation and biomarker tracking.
- Facilitates risk-adjusted advancement decisions by providing robust in vivo efficacy data.
Pipeline & Workflow Integration
This intra-peritoneal transplantation protocol positions AML model generation at the interface of early discovery, lead identification, and preclinical validation.
- Discovery Biology: Supports hypothesis testing and mechanistic de-risking of AML targets using lineage-negative and LSK donor populations.
- Screening: Delivers reproducible, quantitative engraftment and leukocytosis readouts for compound evaluation.
- Analytics: Enables flow cytometry, qPCR, and histological analyses to compare disease burden and infiltration across conditions.
- Translational Research: Maintains disease relevance and biomarker continuity through serial transplantation and multi-tissue analysis.
- Enterprise Reuse: Establishes a scalable, standardized model adaptable across AML research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in AML target validation.
- Operational Value: Streamlines model generation with standardized, reproducible, and scalable procedures.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by reducing technical barriers and late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of AML therapeutic candidates.
Implementation Considerations
- Requires expertise in murine handling, bone marrow isolation, and flow cytometry analysis.
- Needs access to sterile surgical instruments, cell sorting, and analytical infrastructure for multi-tissue assessment.
- Demands cross-team standardization of transplantation and monitoring protocols for reproducibility.
- Adaptable to both lineage-negative and LSK donor populations without significant efficiency differences.
- Primary intra-peritoneal transplantation may require longer disease development time compared to retro-orbital injection.
Biopharma FAQs
Why does null hypothesis testing matter for AML target validation?
Null hypothesis testing using this AML model enables objective assessment of whether specific donor cell populations or transplantation routes impact disease induction, supporting rigorous target validation and reducing mechanistic uncertainty in early discovery.
How does independent variable isolation fit the AML discovery pipeline?
By comparing lineage-negative and LSK donor populations and transplantation routes, the protocol isolates key variables, clarifying their roles in AML initiation and supporting mechanistic de-risking for therapeutic hypothesis testing.
What do quantitative dependent variable measurements enable in AML models?
Quantitative readouts such as leukocytosis, engraftment levels, and tissue infiltration measured by flow cytometry and qPCR enable robust comparison of disease burden, informing compound efficacy and model reproducibility.
Why are replication requirements critical for cross-functional AML research?
Standardized, reproducible transplantation and monitoring protocols ensure that results are consistent across teams, facilitating reliable cross-functional collaboration and accelerating translational advancement.
Which statistical analysis capabilities are required before AML model implementation?
Statistical analysis of engraftment rates, leukocytosis thresholds, and tissue infiltration is essential to validate model consistency, compare experimental groups, and support data-driven go/no-go decisions in the discovery pipeline.
